Across TCGA pan-cancer cohorts, SEMA5B mass-spec protein differs between tumor and matched normal tissue in 2 of 18 cancer types tested, making tumor–normal expression one of SEMA5B’s most consistent transcriptional readouts.
The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where SEMA5B mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types SEMA5B is over-expressed in tumor.
CCRCC and LUAD are the cancer types where SEMA5B tumor–normal differential expression is most reproducible.